ReviewClinics and practice2021
Malignant Phyllodes Tumor of the Breast: A Practice Review.
Review in Clinics and practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Management and Outcomes of Metastatic and Recurrent Malignant Phyllodes Tumors of the Breast: A Systematic Literature Review.European journal of breast health · 2023Pooled it
- A deceptive fungating breast mass: giant fibroadenoma with multiple epidermal inclusion cysts mimicking malignancy.Future science OA · 2026Article
- Young Adult With Malignant Phyllodes Undergoing Adjuvant Radiotherapy With Bolus.Clinical case reports · 2026Article
- Article
- Long-term outcomes of rare pure histological subtypes of breast cancer in a tertiary single-center retrospective cohort.Discover oncology · 2026Article
- Giant Malignant Phyllodes Tumor with Secondary Thyroid Involvement.Diseases (Basel, Switzerland) · 2026Article
- Malignant Phyllodes Tumor in Adolescent Females: A Report of Three Cases and Review of the Literature.Case reports in surgery · 2026Article
- Malignant phyllodes tumor of the breast with heterologous osteosarcomatous and pleomorphic liposarcomatous differentiation: a rare case report and literature review.Frontiers in oncology · 2026Article
- Malignant Mesenchymal Tumors of the Breast: Current Challenges and New Perspectives on Primary Sarcomas and Malignant Phyllodes Tumors.Life (Basel, Switzerland) · 2025Review
- Malignant phyllodes tumor of the breast with bilateral ductal carcinoma in situ and postoperative distant metastasis: a case report.Translational cancer research · 2024Article
- Recurrent and transformation of borderline to malignant phyllodes tumour with osteoid differentiation: a case report and literature review.Frontiers in oncology · 2024Article
- Primary osteosarcoma of the breast during lactation: a case report and literature review.Frontiers in oncology · 2024Article
- IntragenicCancers · 2023Article
- Metabolic coupling in phyllodes tumor of the breast and its association with tumor progression.Oncology letters · 2023Article
- CD146 promotes malignant progression of breast phyllodes tumor through suppressing DCBLD2 degradation and activating the AKT pathway.Cancer communications (London, England) · 2023Article
- A case of malignant phyllodes tumor that responded to pazopanib and developed pneumothorax.International cancer conference journal · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPhyllodes tumor (PT) of the breast, particularly malignant phyllodes tumor (mPT), is a rare fibroepithelial neoplasm. A complex diagnosis is based on pathologic, radiologic, and clinical findings, with controversies about what is the best therapeutic strategy.
objectiveOur objective was to provide an overview of the clinical, pathologic, and therapeutic aspects of this rare tumor.
conclusionsmPT is a rare presentation of breast cancer and a challenge in clinical practice. A multidisciplinary approach should take into account some aspects like pathogenic mutations and hereditary syndromes. Oncologic surgery is the fundamental approach, and the use of adjuvant therapies is still controversial due to the lack of clinical trials. Treatment recommendations should be individualized according to patient risk and preferences. Prospective studies are fundamental to clarifying the best treatment for these tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.